^™middle.

Gathering signals...

Nyrada (ASX:NYR) — Material Events

ASX:NYR · 8 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed

Significant Score 75–89

7

Nyrada Advances Xolatryp with Phase I Success and AU$8.25M RaiseMedium

Nyrada completes Phase I trial, plans Phase IIa for Xolatryp with AU$8.25M capital raise

21 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85

Nyrada Doses First Patient in Xolatryp Phase IIa Trial, Secures US Patent AllowanceMedium

Nyrada advances Xolatryp Phase IIa trial, secures US patent allowance, and reports strong cash position

27 July 2026 ·Quarterly Activities Report and Appendix 4C ·85

Nyrada Clears Ethics Hurdle to Launch Phase IIa Heart Attack TrialMedium

Nyrada gets ethics approval to start Phase IIa trial of Xolatryp for heart attack treatment

8 Jan 2026 ·Clinical Trial Announcement ·80

Nyrada Advances Xolatryp Phase IIa Trial with AU$6.74M Cash and Expanded Oncology ResearchMedium

Nyrada gains ethics approval for Phase IIa Xolatryp trial, reports AU$6.74M cash and AU$2.45M R&D rebate expected

15 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·80

Nyrada Advances Xolatryp Trial with Ethics Nod, Holds AU$7.12M CashMedium

Nyrada gets ethics approval for Phase IIa Xolatryp trial; strong cash position at AU$7.12M

23 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·80

Nyrada’s Xolatryp Advances with Strong Mitochondrial Protection DataMedium

Nyrada's Xolatryp Shows Mitochondrial Protection in Preclinical Studies, Phase IIa Trial on Track

16 Sept 2025 ·Clinical Trial Update ·80

Nyrada’s Xolatryp Clears Safety Hurdle, Phase IIa Trial Set for Early 2026Medium

Nyrada's Xolatryp Phase I Trial Meets Safety Endpoints, Phase IIa Trial on Track for 2026

29 Sept 2025 ·Clinical Trial Update ·80

Notable Score 50–74

1

Nyrada’s Xolatryp Advances as Losses Deepen to $3.19M in H1 2026Medium

Nyrada reports $3.19M half-year loss; Xolatryp advances to Phase IIa trial

18 Feb 2026 ·Appendix 4D Half-year report ·70

Not Assessed Low Score, or missing data

0

No articles in this tier for the last 12 months.

Market Mentions 4 - appeared in market wrap coverage

These are market wrap articles where Nyrada (ASX:NYR) was mentioned. They reflect broader market coverage, not company-specific announcements.

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026

Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Healthcare Wrap - Week 4 (19 Jan -> 23 Jan) 2026